全文获取类型
收费全文 | 19888篇 |
免费 | 1922篇 |
国内免费 | 305篇 |
专业分类
耳鼻咽喉 | 79篇 |
儿科学 | 2210篇 |
妇产科学 | 904篇 |
基础医学 | 1499篇 |
口腔科学 | 59篇 |
临床医学 | 3071篇 |
内科学 | 3381篇 |
皮肤病学 | 136篇 |
神经病学 | 478篇 |
特种医学 | 378篇 |
外科学 | 668篇 |
综合类 | 3413篇 |
现状与发展 | 1篇 |
一般理论 | 1篇 |
预防医学 | 2406篇 |
眼科学 | 79篇 |
药学 | 2248篇 |
55篇 | |
中国医学 | 864篇 |
肿瘤学 | 185篇 |
出版年
2024年 | 94篇 |
2023年 | 353篇 |
2022年 | 795篇 |
2021年 | 1153篇 |
2020年 | 1466篇 |
2019年 | 822篇 |
2018年 | 755篇 |
2017年 | 862篇 |
2016年 | 986篇 |
2015年 | 929篇 |
2014年 | 1580篇 |
2013年 | 1718篇 |
2012年 | 1273篇 |
2011年 | 1319篇 |
2010年 | 934篇 |
2009年 | 785篇 |
2008年 | 730篇 |
2007年 | 844篇 |
2006年 | 683篇 |
2005年 | 539篇 |
2004年 | 503篇 |
2003年 | 460篇 |
2002年 | 292篇 |
2001年 | 215篇 |
2000年 | 182篇 |
1999年 | 183篇 |
1998年 | 151篇 |
1997年 | 172篇 |
1996年 | 141篇 |
1995年 | 114篇 |
1994年 | 106篇 |
1993年 | 85篇 |
1992年 | 82篇 |
1991年 | 88篇 |
1990年 | 51篇 |
1989年 | 67篇 |
1988年 | 56篇 |
1987年 | 48篇 |
1986年 | 50篇 |
1985年 | 60篇 |
1984年 | 54篇 |
1983年 | 45篇 |
1982年 | 49篇 |
1981年 | 49篇 |
1980年 | 43篇 |
1979年 | 31篇 |
1978年 | 28篇 |
1977年 | 18篇 |
1976年 | 16篇 |
1973年 | 10篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
71.
新生鼠脑损伤后松果体细胞的一氧化氮合酶与细胞凋亡关系的初步研究 总被引:1,自引:0,他引:1
为了探讨新生鼠发生缺氧缺血性脑损伤时松果体细胞的诱生型一氧化氮合酶 ( i NOS)表达与松果体细胞凋亡及形态学改变的关系 ,用 7日龄新生 Wistar大鼠 ,结扎左侧颈总动脉 ,术后 2 h吸入 8%浓度氧 2 h,建立新生儿缺氧缺血性脑病模型( HIBD)。分别于建模后 0 h、2 4h、48h处死动物 ,剥取松果体 ,观察松果体细胞的 i NOS表达及细胞凋亡 ,电镜观察松果体形态学改变。结果表明 :( 1)新生鼠脑损伤后松果体的 i NOS在 0 h、2 4h含量与对照组相比明显升高 ;( 2 )脑损伤后松果体凋亡细胞早期明显增多 ,尤以 0 h、2 4h为主 ;( 3)电镜观察 :脑损伤后松果体的形态学也以 0 h、2 4h改变为明显 ,出现线粒体明显肿胀、粗面内质网极度扩张、细胞变性。提示 :( 1)新生鼠缺氧缺血性脑损伤后 0 h、2 4h松果体细胞的 i NOS表达增加 ,以后逐渐下降 ,48h表达减少。 ( 2 ) TUNEL法原位检测细胞凋亡与 i NOS表达同步改变 ,i NOS表达对细胞凋亡有促进作用。 ( 3) i NOS表达和细胞凋亡参与了新生鼠缺氧缺血性脑损伤后松果体细胞形态学改变 相似文献
72.
Children with recurrent lower respiratory tract infection (RLRI) may respond poorly to polysaccharide antigens. To examine how such children respond to a polysaccharide coupled to a protein carrier, we immunized 15 children with RLRI aged 8–69 months and 15 carefully age-matched healthy controls once with a Haemophilus influenzae type b (Hib) conjugate vaccine. Total IgG subclasses, total antipolysaccharide Hib antibodies, and antipolysaccharide Hib antibodies of IgM, IgG, IgA, and IgG 1–4 specificity were determined by ELISA. There were no significant differences between the two groups in any single total IgG subclass, but total IgG measured as the sum of all four subclasses was significantly lower in the children with RLRI than in the controls ( P = 0.036). Before vaccination, the children with RLRI had significantly less IgG antipolysaccharide Hib antibody than the controls ( P = 0.005), whereas 1 month later they had significantly more IgM antibody (P = 0.038). No other significant differences were found between the groups before or after immunization with respect to antipolysaccharide Hib antibodies. Since naturally occurring IgG antibodies are thought to be aquired partly as a consequence of antigenic stimulation on mucosal surfaces, we hypothesize that the low level of specific IgG found before immunization, as well as the low total IgG in the children with RLRI, may reflect an impaired ability to prime through mucosal surfaces. This is supported by our finding of an increased IgM response to Hib conjugate vaccine in these children, since this isotype predominates in the primary immune response, i.e., in the absence of immunologic memory. In conclusion, children with RLRI can be protected against invasive Hib infection as well as healthy children, but may have an immunodeficiency characterized by defective ability to respond to antigenic stimulation on mucosal surfaces. 相似文献
73.
Pinborg A Loft A Rasmussen S Schmidt L Langhoff-Roos J Greisen G Andersen AN 《Human reproduction (Oxford, England)》2004,19(2):435-441
BACKGROUND: In Denmark, one-third of twin pregnancies are the result of IVF/ICSI treatment. Limited data on neonatal outcome in IVF/ICSI twins are available in the literature. METHODS: A register study was conducted on neonatal morbidity and mortality in a complete national twin cohort including all 3438 (3393 live-born) IVF/ICSI and 10,362 (10,239 live-born) non-IVF/ICSI twins born between 1995 and 2000. Twins were identified in the National Medical Birth Registry and dichotomized into IVF/ICSI and non-IVF/ICSI by cross-reference with the Danish IVF Registry. Data on neonatal morbidity and mortality were retrieved from the Danish Patient Registry and the Danish Registry of Causes of Deaths. In order to exclude monozygotic twins, sub-analyses on unlike-sex twins were conducted. RESULTS: A birth weight discordance of >20% was observed in 20.6% of IVF/ICSI versus 15.7% of control twin pairs (P < 0.001). The risk of discordant birth weight >20% was OR 1.29 (95% CI 1.04-1.58) in unlike-sex IVF/ICSI twins versus control twins. The risk of delivery at <37 completed weeks and birth weight <2500 g was similar in the two cohorts; however, in unlike-sex IVF/ICSI versus control twins the risk of delivery at <37 weeks and birth weight <2500 g was OR 1.22 (95% CI 1.09-1.38) and OR 1.25 (1.11-1.40) respectively. After stratification for maternal age and parity, these risks disappeared. IVF/ICSI twins carried a higher risk of admittance to a neonatal intensive care unit (NICU) than control twins (OR 1.18, 95% CI 1.09-1.27), and this was even more pronounced in unlike-sex twins [OR 1.34 (95% CI 1.19-1.51)]. No differences were observed in malformation or mortality rates between the two cohorts. CONCLUSIONS: Despite higher birth weight discordance and more NICU admissions among IVF/ICSI twins, neonatal outcome in IVF/ICSI twins seems to be comparable with that of non-IVF/ICSI twins, when only dizygotic twins were considered in the comparisons. 相似文献
74.
Martinez X Regner M Kovarik J Zarei S Hauser C Lambert PH Leclerc C Siegrist CA 《Virology》2003,305(2):428-435
The relative immaturity of the neonatal immune system limits CD4(+) Th1 and cytotoxic T lymphocyte (CTL) responses, and represents a significant challenge for the development of vaccines against intracellular pathogens. In this report, we demonstrate the ability of a non-replicative delivery system based on parvovirus-like particles (VLP) to induce CTL responses in the neonatal period. A single immunization of 1-week-old BALB/c mice with recombinant VLP carrying a CD8(+) T cell determinant from lymphocytic choriomeningitis virus (VLP-LCMV) induced antigen-specific CD8(+) cytotoxic T cells that were similar to those elicited by adult immunization, as assessed by cytotoxic activity, interferon (IFN)-gamma secretion, cytotoxic precursor cell frequencies, in vitro avidity for antigen and protective activity against viral challenge. These CTL responses are elicited within 2 weeks of a single immunization, in the absence of adjuvant and independently of the presence and help of CD4(+) T cells, highlighting the potential of VLP as candidate vaccine vectors in early life. 相似文献
75.
重症监护病房中呼吸机相关肺炎的病原学和耐药性特征 总被引:2,自引:0,他引:2
目的探讨重症监护病房(ICU)中呼吸机相关肺炎(VAP)的流行病学、病原菌分布、耐药性特征。方法对广州市3所三级甲等医院ICU发生VAP的53例患者进行前瞻性研究,对病原菌进行细菌鉴定和耐药性分析。结果VAP平均发病时间为机械通气后7.8d。97株病原菌中革兰阴性细菌58株(59.8%),革兰阳性细菌23株(23.7%),真菌16株(16.5%)。最常见病原菌分别为铜绿假单胞菌16株(16.5%),金黄色葡萄球菌13株(13.4%),嗜麦芽窄食单胞菌8株(8.2%),肺炎克雷伯菌8株(8.2%),白色念珠菌8株(8.2%)。耐甲氧西林金黄色葡萄球菌(MRSA)检出率为100.0%;未发现耐万古霉素金黄色葡萄球菌;VAP病原菌存在严重的多重耐药性。结论ICU中VAP的病原菌构成以革兰氏阴性杆菌为主且呈现多重耐药现象,适当的经验性抗菌治疗应以病原学和耐药性的监测结果为依据。 相似文献
76.
Forty-three bronchoalveolar lavage (BAL) specimens from 40 immunocompromised patients were studied for the presence of cytomegalovirus (CMV) by rapid diagnostic methods. DNA in situ hybridization, cytology, and immunofluorescence were compared to conventional cell culture. Eleven (25%) of the 43 BAL samples grew CMV in culture. In situ hybridization detected 6 of these 11 for sensitivity, specificity, and predictive values of positive and negative of 55%, 94%, 75%, and 86%, respectively. Cytology had a sensitivity of 73% and specificity of 100%. Six Papanicolaou-stained cytospins were screened cytologically versus one hybridization cytospin, and the higher sensitivity of cytology may reflect this extensive sampling. The immunofluorescent method had a sensitivity equal to that of cytology (73%): however, the specificity (72%) was significantly less than that of either the probe or cytology. These data suggest that although in situ hybridization can be a rapid, useful method for detecting CMV in BAL specimens, cytology appears to be a more sensitive method. 相似文献
77.
Payeras A Martinez P Milà J Riera M Pareja A Casal J Matamoros N 《Clinical and experimental immunology》2002,130(2):271-278
The aim of the study was to determine possible factors related to the risk of developing recurrent bacterial respiratory tract infections in HIV-1-infected patients, regardless of the degree of immune cellular impairment. Thirty-three HIV-1 seropositive patients with previous repetitive bacterial respiratory tract infections (case group), 33 HIV-1 seropositive controls (matched by CD4-cell counts) without these antecedents and 27 healthy controls were studied before and after administration of pneumococcal and Haemophilus influenzae type b vaccines. Clinical or toxicological variables, cutaneous tests, complement factors, beta2-microglobulin, serum IgM, IgA, IgG and subclasses, specific antibodies (IgG, IgG2, IgA) against pneumococcal vaccine and polyribosylribitol phosphate (PRP), their avidity, opsonophagocytosis and IgG(2)m and Fc(gamma)RIIa allotypes were determined. A history of drug abuse (P = 0.001), less likelihood of receiving high activity antiretroviral treatment high activity antiretroviral treatment (HAART) (P = 0.01), higher levels of HIV-1 viral load (P < 0.05), serum IgG (P < 0.01) and beta2-microglobulin (P < 0.01) were observed in the case group. Also, a lower increase in specific antibodies to pneumococcal vaccine and PRP was demonstrated in the cases in comparison with the two control groups. No differences were observed in the avidity of antibodies, opsonophagocytic capacity or IgG(2)m and Fc(gamma)RIIa allotypes between the three groups. These data indicate that vaccination strategies against encapsulated bacteria can be unsuccessful in the HIV-1-infected patients presenting repetitive bacterial respiratory tract infections if behavioural aspects or measures to improve adherence to HAART therapies are not considered. 相似文献
78.
H. Lode P. Magyar J. F. Muir U. Loos K. Kleutgens 《Clinical microbiology and infection》2004,10(6):512-520
A double-blind, double-dummy, multicentre, multinational, parallel-group study was designed to establish proof of equivalence between oral gatifloxacin and oral co-amoxiclav in the treatment of 462 patients with mild-to-moderate community-acquired pneumonia. Eligible patients were randomised equally to either gatifloxacin 400 mg once-daily plus matching placebo for 5-10 days, or amoxycillin 500 mg + clavulanic acid 125 mg three-times-daily for 5-10 days. The primary efficacy endpoint was clinical response (clinical cure plus improvement) at the end of treatment. Overall, a successful clinical response was achieved in 86.8% of gatifloxacin-treated patients, compared with 81.6% of those receiving co-amoxiclav, while corresponding rates of bacteriological efficacy (eradication plus presumed eradication) were 83.1% and 78.7%, respectively. The safety and tolerability profile of gatifloxacin was comparable to that of co-amoxiclav, with adverse gastrointestinal events, e.g., diarrhoea and nausea, being the most common treatment-related adverse events in both groups. The study showed no evidence of gatifloxacin-induced phototoxicity, musculoskeletal disorders, or hepatic and renal problems. Overall, this study showed that gatifloxacin was equivalent clinically to a standard course of co-amoxiclav in patients with community-acquired pneumonia, and that gatifloxacin was safe and well-tolerated. 相似文献
79.
M. Tamm T. Todisco C. Feldman J. Garbino F. Blasi P. Hogan P. J. de Caprariis I. M. Hoepelman 《Clinical microbiology and infection》2007,13(2):162-171
This study compared patients with moderate-to-severe community-acquired pneumonia (CAP) requiring hospitalisation, who received initial therapy with either intravenous ceftriaxone plus intravenous azithromycin, followed by step-down to oral azithromycin (n = 135), with patients who received intravenous ceftriaxone combined with either intravenous clarithromycin or erythromycin, followed by step-down to either oral clarithromycin or erythromycin (n = 143). Clinical and bacteriological outcomes were evaluated at the end of therapy (EOT; day 12-16) or at the end of study (EOS; day 28-35). At baseline, mean APACHE II scores were 13.3 and 12.6, respectively, with >50% of patients classified as Fine Pneumonia Severity Index (PSI) category IV or V. Clinical success rates (cure or improvement) in the modified intent-to-treat (MITT) population at EOT were 84.3% in the ceftriaxone/azithromycin group and 82.7% in the ceftriaxone/clarithromycin or erythromycin group. At EOS, MITT success rates (cure only) were 81.7% and 75.0%, respectively. Equivalent success rates in the clinically evaluable population were 83% and 87%, respectively, at EOT, and 79% and 78%, respectively, at EOS. MITT bacteriological eradication rates were 73.2% and 67.4%, respectively, at EOT, and 68.3% vs. 60.9%, respectively, at EOS. Mean length of hospital stay (LOS) was 10.7 and 12.6 days, and the mean duration of therapy was 9.5 and 10.5 days, respectively. The incidence of infusion-related adverse events was 16.3% and 25.2% (p 0.04), respectively. An intravenous-to-oral regimen of ceftriaxone/azithromycin was at least equivalent in efficacy and safety to the comparator regimen and appeared to be a suitable treatment option for hospitalised patients with CAP. 相似文献
80.